Progressive fibrosing interstitial lung disease in rheumatoid arthritis: A retrospective study.
disease progression
epidemiological characteristics
interstitial lung disease
lung fibrosis
rheumatoid arthritis
survival
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
08
2022
accepted:
08
11
2022
entrez:
19
12
2022
pubmed:
20
12
2022
medline:
20
12
2022
Statut:
epublish
Résumé
Rheumatoid arthritis associated-interstitial lung disease (RA-ILD) is the most common pulmonary manifestation of rheumatoid arthritis (RA) and an important cause of mortality. In patients suffering from interstitial lung diseases (ILD) from different etiologies (including RA-ILD), a significant proportion is exhibiting a fibrotic progression despite immunosuppressive therapies, defined as progressive fibrosing interstitial lung disease (PF-ILD). Here, we report the frequency of RA-ILD and PF-ILD in all RA patients' cohort at University Hospital of Liège and compare their characteristics and outcomes. Patients were retrospectively recruited from 2010 to 2020. PF-ILD was defined based on functional, clinical and/or iconographic progression criteria within 24 months despite specific anti-RA treatment. Out of 1,500 RA patients, about one third had high-resolution computed tomography (HRCT) performed, 89 showed RA-ILD and 48 PF-ILD. RA-ILD patients were significantly older than other RA patients (71 old of median age vs. 65, We identified a prevalence of PF-ILD of 3% in a general RA population. The PF-ILD cohort did not seem to be different in terms of demographic characteristics and mortality compared to RA-ILD patients who did not exhibit the progressive phenotype yet.
Sections du résumé
Background and objective
UNASSIGNED
Rheumatoid arthritis associated-interstitial lung disease (RA-ILD) is the most common pulmonary manifestation of rheumatoid arthritis (RA) and an important cause of mortality. In patients suffering from interstitial lung diseases (ILD) from different etiologies (including RA-ILD), a significant proportion is exhibiting a fibrotic progression despite immunosuppressive therapies, defined as progressive fibrosing interstitial lung disease (PF-ILD). Here, we report the frequency of RA-ILD and PF-ILD in all RA patients' cohort at University Hospital of Liège and compare their characteristics and outcomes.
Methods
UNASSIGNED
Patients were retrospectively recruited from 2010 to 2020. PF-ILD was defined based on functional, clinical and/or iconographic progression criteria within 24 months despite specific anti-RA treatment.
Results
UNASSIGNED
Out of 1,500 RA patients, about one third had high-resolution computed tomography (HRCT) performed, 89 showed RA-ILD and 48 PF-ILD. RA-ILD patients were significantly older than other RA patients (71 old of median age vs. 65,
Conclusion
UNASSIGNED
We identified a prevalence of PF-ILD of 3% in a general RA population. The PF-ILD cohort did not seem to be different in terms of demographic characteristics and mortality compared to RA-ILD patients who did not exhibit the progressive phenotype yet.
Identifiants
pubmed: 36530900
doi: 10.3389/fmed.2022.1024298
pmc: PMC9748274
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1024298Informations de copyright
Copyright © 2022 Denis, Henket, Ernst, Maes, Thys, Regnier, Malaise, Frix, Gester, Desir, Meunier, Louis, Malaise and Guiot.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Chest. 2009 Nov;136(5):1397-1405
pubmed: 19892679
Eur Respir Rev. 2011 Jun;20(120):85-97
pubmed: 21632796
Chest. 2020 Aug;158(2):646-659
pubmed: 32268131
Eur Respir J. 2011 Jun;37(6):1411-7
pubmed: 20884744
Front Med (Lausanne). 2021 Oct 13;8:743977
pubmed: 34722582
Eur J Intern Med. 2013 Oct;24(7):597-603
pubmed: 23916467
Lancet Respir Med. 2020 Sep;8(9):925-934
pubmed: 32890499
Eur Respir J. 2016 Feb;47(2):588-96
pubmed: 26585429
Arthritis Rheum. 2010 Jun;62(6):1583-91
pubmed: 20155830
Eur Respir J. 2021 Feb 11;57(2):
pubmed: 32646919
Ann Rheum Dis. 2008 Oct;67(10):1488-92
pubmed: 18413445
Eur Respir Rev. 2019 Feb 27;28(151):
pubmed: 30814139
Curr Opin Pulm Med. 2020 Sep;26(5):477-486
pubmed: 32701675
Ann Rheum Dis. 2017 Oct;76(10):1700-1706
pubmed: 28611082
Clin Rheumatol. 2011 Feb;30(2):217-21
pubmed: 20503061
N Engl J Med. 2018 Dec 6;379(23):2209-2219
pubmed: 30345907
Autoimmun Rev. 2022 May;21(5):103056
pubmed: 35121155
Lancet. 2016 Oct 22;388(10055):2023-2038
pubmed: 27156434
Int Immunopharmacol. 2019 Sep;74:105700
pubmed: 31228816
Autoimmun Rev. 2013 Sep;12(11):1076-84
pubmed: 23684699
Semin Respir Crit Care Med. 2014 Apr;35(2):222-38
pubmed: 24668537
Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47
pubmed: 35486072
Arthritis Rheum. 2006 Jan;54(1):38-46
pubmed: 16385494
Lancet Respir Med. 2020 May;8(5):453-460
pubmed: 32145830
Biomed Res Int. 2013;2013:759760
pubmed: 24205507
Eur Respir J. 2021 May 13;57(5):
pubmed: 33303554
Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):528-35
pubmed: 9279235
Eur Respir Rev. 2021 Jun 23;30(160):
pubmed: 34168062
Eur Respir Rev. 2015 Mar;24(135):1-16
pubmed: 25726549
Int J Rheum Dis. 2010 Oct;13(4):284-7
pubmed: 21199462
Chest. 2014 Mar 1;145(3):454-463
pubmed: 24590021
ERJ Open Res. 2022 Jan 24;8(1):
pubmed: 35083316
Rev Invest Clin. 2015 Sep-Oct;67(5):280-6
pubmed: 26696331
Arthritis Rheumatol. 2017 Mar;69(3):542-549
pubmed: 27788297
Eur Respir Rev. 2018 Dec 21;27(150):
pubmed: 30578335
Arthritis Rheum. 1999 Mar;42(3):415-20
pubmed: 10088762
Respirology. 2014 May;19(4):493-500
pubmed: 24372981
Clin Rheumatol. 2021 Apr;40(4):1211-1220
pubmed: 32794076
Am J Physiol Lung Cell Mol Physiol. 2018 Jun 1;314(6):L998-L1009
pubmed: 29543042
Clin Rheumatol. 2018 Nov;37(11):3057-3062
pubmed: 30291470
N Engl J Med. 2011 Apr 21;364(16):1503-12
pubmed: 21506741
J Clin Med. 2020 Apr 10;9(4):
pubmed: 32290218
Am J Respir Crit Care Med. 2011 Feb 1;183(3):372-8
pubmed: 20851924
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595
Rheumatology (Oxford). 2014 Sep;53(9):1676-82
pubmed: 24758887
N Engl J Med. 2019 Oct 31;381(18):1718-1727
pubmed: 31566307